<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38391754</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3425</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>Brain sciences</Title><ISOAbbreviation>Brain Sci</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci14020180</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) involves the degeneration of motor neurons and debilitating and possibly fatal symptoms. The COVID-19 pandemic directly affected the quality of life of this group, and the SARS-CoV-2 infection accelerated the present neuroinflammatory process. Furthermore, studies indicate that the infection may have led to the development of the pathology. Thus, the scenario after this pandemic presents "long-lasting COVID" as a disease that affects people who have been infected. From this perspective, studying the pathophysiology behind ALS associated with SARS-CoV-2 infection and possible supporting therapies becomes necessary when we understand the impact on the quality of life of these patients. Thus, the purinergic system was trained to demonstrate how its modulation can add to the treatment, reduce disease progression, and result in better prognoses. From our studies, we highlight the P2X7, P2X4, and A2AR receptors and how their activity can directly influence the ALS pathway.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le&#xe3;o Batista Sim&#xf5;es</LastName><ForeName>J&#xfa;lia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1652-9692</Identifier><AffiliationInfo><Affiliation>Medical School, Federal University of Fronteira Sul, Chapec&#xf3; 89815-899, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webler Eichler</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9088-1742</Identifier><AffiliationInfo><Affiliation>Medical School, Federal University of Fronteira Sul, Chapec&#xf3; 89815-899, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raitz Siqueira</LastName><ForeName>Maria Lu&#xed;za</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0003-2532-6931</Identifier><AffiliationInfo><Affiliation>Medical School, Federal University of Fronteira Sul, Chapec&#xf3; 89815-899, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho Braga</LastName><ForeName>Ge&#xf3;rgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0384-9934</Identifier><AffiliationInfo><Affiliation>Medical School, Federal University of Fronteira Sul, Chapec&#xf3; 89815-899, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagatini</LastName><ForeName>Margarete Dulce</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-9263-4980</Identifier><AffiliationInfo><Affiliation>Graduate Program in Medical Sciences, Federal University of Fronteira Sul, Chapec&#xf3; 89815-899, SC, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Proj. No 404256/2021-0 and 310606/2021-7).</GrantID><Agency>National Council for Scientific and Technological Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Sci</MedlineTA><NlmUniqueID>101598646</NlmUniqueID><ISSNLinking>2076-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">purinergic</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>10</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38391754</ArticleId><ArticleId IdType="pmc">PMC10886908</ArticleId><ArticleId IdType="doi">10.3390/brainsci14020180</ArticleId><ArticleId IdType="pii">brainsci14020180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abu-Abaa M., Mousa A., Chadalawada S., Abdulsahib A. Bulbar Onset Amyotrophic Lateral Sclerosis in a COVID-19 Patient: A Case Report. Cureus. 2023;15:e37814. doi: 10.7759/cureus.37814.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.37814</ArticleId><ArticleId IdType="pmc">PMC10197023</ArticleId><ArticleId IdType="pubmed">37214058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhou Z. COVID-19 and the risk of Alzheimer&#x2019;s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ann. Clin. Transl. Neurol. 2022;9:1953&#x2013;1961. doi: 10.1002/acn3.51688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51688</ArticleId><ArticleId IdType="pmc">PMC9735364</ArticleId><ArticleId IdType="pubmed">36321943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Kang L., Wang Y., Yang B., Zhang C., Lu Y., Kang L. Microglia in motor neuron disease: Signaling evidence from last 10 years. Dev. Neurobiol. 2022;82:625&#x2013;638. doi: 10.1002/dneu.22905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.22905</ArticleId><ArticleId IdType="pmc">PMC9828749</ArticleId><ArticleId IdType="pubmed">36309345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto V., Pasetto L., Lisi I., Carbonara M., Zangari R., Ferrari E., Punzi V., Luotti S., Bottino N., Biagianti B., et al. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front. Immunol. 2022;13:1070379. doi: 10.3389/fimmu.2022.1070379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1070379</ArticleId><ArticleId IdType="pmc">PMC9798841</ArticleId><ArticleId IdType="pubmed">36591311</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsagkaris C., Bilal M., Aktar I., Aboufandi Y., Tas A., Aborode A.T., Suvvari T.K., Ahmad S., Shkodina A., Phadke R., et al. Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19. Curr. Alzheimer Res. 2022;19:641&#x2013;657. doi: 10.2174/1567205019666220908084559.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205019666220908084559</ArticleId><ArticleId IdType="pubmed">36089786</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider H.F., Szczepek A.J. Editorial: Neurotological consequences of long COVID. Front. Neurol. 2022;13:1087896. doi: 10.3389/fneur.2022.1087896.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.1087896</ArticleId><ArticleId IdType="pmc">PMC9720380</ArticleId><ArticleId IdType="pubmed">36479046</ArticleId></ArticleIdList></Reference><Reference><Citation>Trampu&#x17e; S.R., Vogrinc D., Gori&#x10d;ar K., Dol&#x17e;an V. Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature. Front. Mol. Neurosci. 2023;16:1123955. doi: 10.3389/fnmol.2023.1123955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2023.1123955</ArticleId><ArticleId IdType="pmc">PMC10064073</ArticleId><ArticleId IdType="pubmed">37008787</ArticleId></ArticleIdList></Reference><Reference><Citation>Feghali E.J., Challa A., Mahdi M., Acosta E., Jackson J. New-Onset Amyotrophic Lateral Sclerosis in a Patient who Received the J&amp;J/Janssen COVID-19 Vaccine. Kans. J. Med. 2023;16:69&#x2013;70. doi: 10.17161/kjm.vol16.18969.</Citation><ArticleIdList><ArticleId IdType="doi">10.17161/kjm.vol16.18969</ArticleId><ArticleId IdType="pmc">PMC10035647</ArticleId><ArticleId IdType="pubmed">36970039</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckenzie A.D.J., Garrett T.R., Werry E.L., Kassiou M. Purinergic P2X7 Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis. ACS Chem. Neurosci. 2022;13:1479&#x2013;1490. doi: 10.1021/acschemneuro.2c00133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.2c00133</ArticleId><ArticleId IdType="pubmed">35512313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Ruiz C., Calzaferri F., Garc&#xed;a A.G. P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2020;13:93. doi: 10.3389/fnmol.2020.00093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00093</ArticleId><ArticleId IdType="pmc">PMC7303288</ArticleId><ArticleId IdType="pubmed">32595451</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Amadio S. Rethinking purinergic concepts and updating the emerging role of P2X7 and P2X4 in amyotrophic lateral sclerosis. Neuropharmacology. 2022;221:109278. doi: 10.1016/j.neuropharm.2022.109278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2022.109278</ArticleId><ArticleId IdType="pubmed">36202258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin E., Martinez A., Fayoux A., Carvalho K., Carracedo S., Fernagut P.-O., Koch-Nolte F., Blum D., Bertrand S.S., Bou&#xe9;-Grabot E. Increased surface P2X4 receptors by mutant SOD1 proteins contribute to ALS pathogenesis in SOD1-G93A mice. Cell. Mol. Life Sci. 2022;79:431. doi: 10.1007/s00018-022-04461-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04461-5</ArticleId><ArticleId IdType="pmc">PMC9296432</ArticleId><ArticleId IdType="pubmed">35852606</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrosi N., Finocchi P., Apolloni S., Cozzolino M., Ferri A., Padovano V., Pietrini G., Carri&#xec; M.T., Volont&#xe9; C. The Proinflammatory Action of Microglial P2 Receptors Is Enhanced in SOD1 Models for Amyotrophic Lateral Sclerosis. J. Immunol. 2009;183:4648&#x2013;4656. doi: 10.4049/jimmunol.0901212.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901212</ArticleId><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Apolloni S., Parisi C., Amadio S. Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology. 2016;104:180&#x2013;193. doi: 10.1016/j.neuropharm.2015.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.10.026</ArticleId><ArticleId IdType="pubmed">26514402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lak M., Roszek K., Wujak M. Purinergic implication in amyotrophic lateral sclerosis&#x2014;From pathological mechanisms to therapeutic perspectives. Purinergic Signal. 2018;15:1&#x2013;15. doi: 10.1007/s11302-018-9633-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-018-9633-4</ArticleId><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. doi: 10.1186/1471-2377-6-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Arisi I., D&#x2019;Ambrosi N., Storti A.E., Brandi R., D&#x2019;Onofrio M., Volont&#xe9; C. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013;4:e959. doi: 10.1038/cddis.2013.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.491</ArticleId><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Parisi C., Matteucci A., Potenza R.L., Armida M., Popoli P., D&#x2019;Ambrosi N., Volont&#xe9; C. Spinal cord pathology is ameliorated by P2X7 antagonism in SOD1-G93A mouse model of amyotrophic lateral sclerosis. Dis. Model. Mech. 2014;7:1101&#x2013;1109. doi: 10.1242/dmm.017038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.017038</ArticleId><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanovas A., Hern&#xe1;ndez S., Tarabal O., Rossell&#xf3; J., Esquerda J.E. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis. J. Comp. Neurol. 2007;506:75&#x2013;92. doi: 10.1002/cne.21527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21527</ArticleId><ArticleId IdType="pubmed">17990272</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett R., Ly D., Cashman N.R., Sluyter R., Yerbury J.J. P2X7 receptor activation mediates superoxide dismutase 1 (SOD1) release from murine NSC-34 motor neurons. Purinergic Signal. 2022;18:451&#x2013;467. doi: 10.1007/s11302-022-09863-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-022-09863-5</ArticleId><ArticleId IdType="pmc">PMC9832181</ArticleId><ArticleId IdType="pubmed">35478453</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Villafuertes R., Rodr&#xed;guez-Jim&#xe9;nez F.J., Alastrue-Agudo A., Stojkovic M., Miras-Portugal M.T., Moreno-Manzano V. Purinergic Receptors in Spinal Cord-Derived Ependymal Stem/Progenitor Cells and Their Potential Role in Cell-Based Therapy for Spinal Cord Injury. Cell Transplant. 2015;24:1493&#x2013;1509. doi: 10.3727/096368914X682828.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368914X682828</ArticleId><ArticleId IdType="pubmed">25198194</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rivero Vaccari J.P., Bastien D., Yurcisin G., Pineau I., Dietrich W.D., De Koninck Y., Keane R.W., Lacroix S. P2X4 Receptors Influence Inflammasome Activation after Spinal Cord Injury. J. Neurosci. 2012;32:3058&#x2013;3066. doi: 10.1523/JNEUROSCI.4930-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4930-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622016</ArticleId><ArticleId IdType="pubmed">22378878</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.G., Soltysiak K.A., Gao Z.-G., Chang T.-S., Chung E., Jacobson K.A. Tumor necrosis factor &#x3b1;-induced apoptosis in astrocytes is prevented by the activation of P2Y6, but not P2Y4 nucleotide receptors. Biochem. Pharmacol. 2003;65:923&#x2013;931. doi: 10.1016/S0006-2952(02)01614-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-2952(02)01614-3</ArticleId><ArticleId IdType="pmc">PMC3402349</ArticleId><ArticleId IdType="pubmed">12623123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Yamanaka H., Fukuoka T., Dai Y., Obata K., Noguchi K. P2Y12Receptor Upregulation in Activated Microglia Is a Gateway of p38 Signaling and Neuropathic Pain. J. Neurosci. 2008;28:2892&#x2013;2902. doi: 10.1523/JNEUROSCI.5589-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5589-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670682</ArticleId><ArticleId IdType="pubmed">18337420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o A.M., Rei N., Ribeiro J.A. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front. Pharmacol. 2018;9:267. doi: 10.3389/fphar.2018.00267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00267</ArticleId><ArticleId IdType="pmc">PMC5911503</ArticleId><ArticleId IdType="pubmed">29713276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento F., Sebasti&#xe3;o A.M., Ribeiro J.A. Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signal. 2015;11:471&#x2013;480. doi: 10.1007/s11302-015-9465-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-015-9465-4</ArticleId><ArticleId IdType="pmc">PMC4648802</ArticleId><ArticleId IdType="pubmed">26335190</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.-J., Ju T.-C., Chen H.-M., Jang Y.-S., Lee L.-M., Lai H.-L., Tai H.-C., Fang J.-M., Lin Y.-L., Tu P.-H., et al. Activation of AMP-activated protein kinase &#x3b1;1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014;24:787&#x2013;801. doi: 10.1093/hmg/ddu497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu497</ArticleId><ArticleId IdType="pubmed">25256353</ArticleId></ArticleIdList></Reference><Reference><Citation>Potenza R.L., Armida M., Ferrante A., P&#xe8;zzola A., Matteucci A., Puopolo M., Popoli P. Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2013;91:585&#x2013;592. doi: 10.1002/jnr.23185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23185</ArticleId><ArticleId IdType="pubmed">23361938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrobon A.J., Andrejew R., Cust&#xf3;dio R.W.A., Oliveira L.d.M., Scholl J.N., Teixeira F.M.E., de Brito C.A., Glaser T., Kazmierski J., Goffinet C., et al. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. Front. Immunol. 2022;13:1012027. doi: 10.3389/fimmu.2022.1012027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1012027</ArticleId><ArticleId IdType="pmc">PMC9562777</ArticleId><ArticleId IdType="pubmed">36248842</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Garc&#xed;a E., Garc&#xed;a-Tovar S., Alfaro E., Zamarr&#xf3;n E., Mangas A., Galera R., Ru&#xed;z-Hern&#xe1;ndez J.J., Sol&#xe9;-Viol&#xe1;n J., Rodr&#xed;guez-Gallego C., Van-Den-Rym A., et al. Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation. Front. Immunol. 2022;13:847894. doi: 10.3389/fimmu.2022.847894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.847894</ArticleId><ArticleId IdType="pmc">PMC8841513</ArticleId><ArticleId IdType="pubmed">35173744</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Villalba J., Hurtado-Navarro L., Pe&#xf1;&#xed;n-Franch A., Molina-L&#xf3;pez C., Mart&#xed;nez-Alarc&#xf3;n L., Angosto-Bazarra D., Baroja-Mazo A., Pelegrin P. Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates with Disease Severity. Front. Immunol. 2022;13:894470. doi: 10.3389/fimmu.2022.894470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.894470</ArticleId><ArticleId IdType="pmc">PMC9161710</ArticleId><ArticleId IdType="pubmed">35663992</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;cuyer D., Nardacci R., Tannous D., Gutierrez-Mateyron E., Deva Nathan A., Subra F., Di Primio C., Quaranta P., Petit V., Richetta C., et al. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection. Front. Immunol. 2023;14:1270081. doi: 10.3389/fimmu.2023.1270081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1270081</ArticleId><ArticleId IdType="pmc">PMC10619763</ArticleId><ArticleId IdType="pubmed">37920468</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues T.S., de S&#xe1; K.S., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gon&#xe7;alves A.V., Perucello D.B., Andrade W.A., Castro R., et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2020;218:e20201707. doi: 10.1084/jem.20201707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Qu R., Junqueira C., Kaffe E., Mirza H., Zhao J., Brewer J.R., Han A., Steach H.R., Israelow B., et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606:585&#x2013;593. doi: 10.1038/s41586-022-04802-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Israelow B., Mirza H., Zhao J., Qu R., Kaffe E., Song E., Halene S., Meffre E., Kluger Y., et al. A humanized mouse model of chronic COVID-19. Nat. Biotechnol. 2021;40:906&#x2013;920. doi: 10.1038/s41587-021-01155-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01155-4</ArticleId><ArticleId IdType="pmc">PMC9203605</ArticleId><ArticleId IdType="pubmed">34921308</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras F.P., Pontelli M.C., Silva C.M., Toller-Kawahisa J.E., de Lima M., Nascimento D.C., Schneider A.H., Caetit&#xe9; D., Tavares L.A., Paiva I.M., et al. SARS-CoV-2&#x2013;triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 2020;217:e20201129. doi: 10.1084/jem.20201129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201129</ArticleId><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppkes M., Knopf J., Naschberger E., Lindemann A., Singh J., Herrmann I., St&#xfc;rzl M., Staats L., Mahajan A., Schauer C., et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine. 2020;58:102925. doi: 10.1016/j.ebiom.2020.102925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102925</ArticleId><ArticleId IdType="pmc">PMC7397705</ArticleId><ArticleId IdType="pubmed">32745993</ArticleId></ArticleIdList></Reference><Reference><Citation>Aymonnier K., Ng J., Fredenburgh L.E., Zambrano-Vera K., M&#xfc;nzer P., Gutch S., Fukui S., Desjardins M., Subramaniam M., Baron R.M., et al. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 2022;6:2001&#x2013;2013. doi: 10.1182/bloodadvances.2021005949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005949</ArticleId><ArticleId IdType="pmc">PMC8741335</ArticleId><ArticleId IdType="pubmed">34991159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Liu X., Gao L., Zhou X., Cao Q., Niu L., Wang J., Zuo D., Li X., Yang Y., et al. HIV-1 Tat enhances purinergic P2Y4 receptor signaling to mediate inflammatory cytokine production and neuronal damage via PI3K/Akt and ERK MAPK pathways. J. Neuroinflamm. 2019;16:71. doi: 10.1186/s12974-019-1466-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1466-8</ArticleId><ArticleId IdType="pmc">PMC6449963</ArticleId><ArticleId IdType="pubmed">30947729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari M., Monika, Varghese R.K., Menon M., Seth P. Astrocytes mediate HIV-1 Tat-induced neuronal damage via ligand-gated ion channel P2X7R. J. Neurochem. 2014;132:464&#x2013;476. doi: 10.1111/jnc.12953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12953</ArticleId><ArticleId IdType="pubmed">25272052</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology. 2016;104:4&#x2013;17. doi: 10.1016/j.neuropharm.2015.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.05.031</ArticleId><ArticleId IdType="pubmed">26056033</ArticleId></ArticleIdList></Reference><Reference><Citation>Savio L.E.B., Andrade M.G.J., Mello P.d.A., Santana P.T., Moreira-Souza A.C.A., Kolling J., Longoni A., Feldbr&#xfc;gge L., Wu Y., Wyse A.T.S., et al. P2X7 Receptor Signaling Contributes to Sepsis-Associated Brain Dysfunction. Mol. Neurobiol. 2016;54:6459&#x2013;6470. doi: 10.1007/s12035-016-0168-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0168-9</ArticleId><ArticleId IdType="pubmed">27730511</ArticleId></ArticleIdList></Reference><Reference><Citation>Savio L.E.B., Leite-Aguiar R., Alves V.S., Coutinho-Silva R., Wyse A.T. Purinergic signaling in the modulation of redox biology. Redox Biol. 2021;47:102137. doi: 10.1016/j.redox.2021.102137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2021.102137</ArticleId><ArticleId IdType="pmc">PMC8479832</ArticleId><ArticleId IdType="pubmed">34563872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., Di Virgilio F. The P2X7 Receptor: A Key Player in IL-1 Processing and Release. J. Immunol. 2006;176:3877&#x2013;3883. doi: 10.4049/jimmunol.176.7.3877.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.7.3877</ArticleId><ArticleId IdType="pubmed">16547218</ArticleId></ArticleIdList></Reference><Reference><Citation>Facci L., Barbierato M., Zusso M., Skaper S.D., Giusti P. Serum amyloid A primes microglia for ATP-dependent interleukin-1&#x3b2; release. J. Neuroinflamm. 2018;15:164. doi: 10.1186/s12974-018-1205-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1205-6</ArticleId><ArticleId IdType="pmc">PMC5970445</ArticleId><ArticleId IdType="pubmed">29803222</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H.B., Ryu J.K., Kim S.U., McLarnon J.G. Modulation of the Purinergic P2X7Receptor Attenuates Lipopolysaccharide-Mediated Microglial Activation and Neuronal Damage in Inflamed Brain. J. Neurosci. 2007;27:4957&#x2013;4968. doi: 10.1523/JNEUROSCI.5417-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5417-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672082</ArticleId><ArticleId IdType="pubmed">17475804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A., Kim H.J., Shin A.H., Thayer S.A. Synapse Loss Induced by Interleukin-1&#x3b2; Requires Pre- and Post-synaptic Mechanisms. J. Neuroimmune Pharmacol. 2012;7:571&#x2013;578. doi: 10.1007/s11481-012-9342-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-012-9342-7</ArticleId><ArticleId IdType="pmc">PMC3415563</ArticleId><ArticleId IdType="pubmed">22311599</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraula G., Lana D., Coppi E., Gentile F., Mello T., Melani A., Galli A., Giovannini M.G., Pedata F., Pugliese A.M. The Selective Antagonism of P2X7 and P2Y1 Receptors Prevents Synaptic Failure and Affects Cell Proliferation Induced by Oxygen and Glucose Deprivation in Rat Dentate Gyrus. PLoS ONE. 2014;9:115273. doi: 10.1371/journal.pone.0115273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0115273</ArticleId><ArticleId IdType="pmc">PMC4272279</ArticleId><ArticleId IdType="pubmed">25526634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue N., Huang H., Zhu X., Han Q., Wang Y., Li B., Liu Q., Wu G., Zhang Y., Yu J. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. J. Neuroinflamm. 2017;14:102. doi: 10.1186/s12974-017-0865-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0865-y</ArticleId><ArticleId IdType="pmc">PMC5424302</ArticleId><ArticleId IdType="pubmed">28486969</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves V.S., Santos S.A.C.S., Leite-Aguiar R., Paiva-Pereira E., dos Reis R.R., Calazans M.L., Fernandes G.G., Ant&#xf4;nio L.S., de Lima E.V., Kurtenbach E., et al. SARS-CoV-2 Spike protein alters microglial purinergic signaling. Front. Immunol. 2023;14:1158460. doi: 10.3389/fimmu.2023.1158460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1158460</ArticleId><ArticleId IdType="pmc">PMC10126242</ArticleId><ArticleId IdType="pubmed">37114062</ArticleId></ArticleIdList></Reference><Reference><Citation>Rud J., Riker R.R., Eldridge A., Lord C., Dekay J.T., May T.L., Gagnon D.J., Sawyer D., Ryzhov S., Seder D.B. Decreased circulating CD73 and adenosine deaminase are associated with disease severity in hospitalized patients with COVID-19. Int. J. Immunopathol. Pharmacol. 2023;37:03946320231185703. doi: 10.1177/03946320231185703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03946320231185703</ArticleId><ArticleId IdType="pmc">PMC10300631</ArticleId><ArticleId IdType="pubmed">37364162</ArticleId></ArticleIdList></Reference><Reference><Citation>Navia A.M., Ben D.D., Lambertucci C., Spinaci A., Volpini R., Marques-Morgado I., Coelho J.E., Lopes L.V., Marucci G., Buccioni M. Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists. Cells. 2020;9:1739. doi: 10.3390/cells9071739.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071739</ArticleId><ArticleId IdType="pmc">PMC7409197</ArticleId><ArticleId IdType="pubmed">32708189</ArticleId></ArticleIdList></Reference><Reference><Citation>Rei N., Rombo D., Ferreira M., Baqi Y., M&#xfc;ller C., Ribeiro J., Sebasti&#xe3;o A., Vaz S. Hippocampal synaptic dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis: Reversal by adenosine A2AR blockade. Neuropharmacology. 2020;171:108106. doi: 10.1016/j.neuropharm.2020.108106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.108106</ArticleId><ArticleId IdType="pubmed">32311420</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Fabbrizio P., Amadio S., Napoli G., Freschi M., Sironi F., Pevarello P., Tarroni P., Liberati C., Bendotti C., et al. Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model. Int. J. Mol. Sci. 2021;22:10649. doi: 10.3390/ijms221910649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910649</ArticleId><ArticleId IdType="pmc">PMC8508678</ArticleId><ArticleId IdType="pubmed">34638992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Ruiz C., Garc&#xed;a-Magro N., Negredo P., Avenda&#xf1;o C., Bhattacharya A., Ceusters M., Garc&#xed;a A.G. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice. Dis. Model. Mech. 2020;13:dmm045732. doi: 10.1242/dmm.045732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.045732</ArticleId><ArticleId IdType="pmc">PMC7648608</ArticleId><ArticleId IdType="pubmed">33174532</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeplaeff L., Wilfling S., Requardt M.V., Herdick M. Current State and Future Directions in the Therapy of ALS. Cells. 2023;12:1523. doi: 10.3390/cells12111523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12111523</ArticleId><ArticleId IdType="pmc">PMC10252394</ArticleId><ArticleId IdType="pubmed">37296644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav A., Huang T.-C., Chen S.-H., Ramasamy T.S., Hsueh Y.-Y., Lin S.-P., Lu F.-I., Liu Y.-H., Wu C.-C. Sodium phenylbutyrate inhibits Schwann cell inflammation via HDAC and NF&#x3ba;B to promote axonal regeneration and remyelination. J. Neuroinflamm. 2021;18:238. doi: 10.1186/s12974-021-02273-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02273-1</ArticleId><ArticleId IdType="pmc">PMC8520633</ArticleId><ArticleId IdType="pubmed">34656124</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokade A.V., Yelne P., Giri A. Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis. Cureus. 2022;14:e30035. doi: 10.7759/cureus.30035.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.30035</ArticleId><ArticleId IdType="pmc">PMC9637445</ArticleId><ArticleId IdType="pubmed">36381733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dion&#xed;sio P.A., Amaral J.D., Ribeiro M.F., Lo A.C., D&#x2019;Hooge R., Rodrigues C.M. Amyloid-&#x3b2; pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol. Aging. 2015;36:228&#x2013;240. doi: 10.1016/j.neurobiolaging.2014.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.08.034</ArticleId><ArticleId IdType="pubmed">25443293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>